Current childhood chronic myeloid leukemia management under tyrosine kinase inhibitor treatment.

Autor: Karadaş N; Pediatric Hematology Department, Ege University School of Medicine, Bornova, Izmir, Turkey. drnihalozdemir@yahoo.com.; Department of Pediatric Hematology, Children's Hospital, Izmir, Turkey. drnihalozdemir@yahoo.com., Göktepe ŞŞÖ; Pediatric Hematology Department, Ege University School of Medicine, Bornova, Izmir, Turkey., Baş İ; Pediatric Hematology Department, Ege University School of Medicine, Bornova, Izmir, Turkey., Ece D; Pediatric Hematology Department, Ege University School of Medicine, Bornova, Izmir, Turkey., Özdemir HH; Pediatric Hematology Department, Ege University School of Medicine, Bornova, Izmir, Turkey., Balkan C; Department of Pediatric Hematology, Children's Hospital, Izmir, Turkey., Kavaklı K; Department of Pediatric Hematology, Children's Hospital, Izmir, Turkey., Aydinok Y; Department of Pediatric Hematology, Children's Hospital, Izmir, Turkey., Karapinar DY; Department of Pediatric Hematology, Children's Hospital, Izmir, Turkey.
Jazyk: angličtina
Zdroj: International journal of hematology [Int J Hematol] 2023 Mar; Vol. 117 (3), pp. 446-455. Date of Electronic Publication: 2022 Nov 19.
DOI: 10.1007/s12185-022-03497-4
Abstrakt: Chronic myeloid leukemia (CML) is very rare during childhood. Tyrosine kinase inhibitors (TKI) provide very good results in terms of survival. The medical records of 15 chronic phase (CP)-CML patients in a university hospital pediatric hematology department between 1997 and 2022 were reviewed retrospectively. Complete hematological response was documented in all patients between 20 and 68 (median 30) days of treatment. Major molecular response was achieved in seven patients within 6 months. Median follow-up for the study group was 79 (range 3-330) months and overall survival was 100%. Three patients (2 blastic transformation, 1 therapy resistant) underwent bone marrow transplantation (BMT) and one with blastic transformation is scheduled to undergo BMT. TKI were discontinued in three patients after a median of 86 (range 73-177) months. The complete molecular remission maintenance period before discontinuation of TKI was 81 (range 62-122) months. While no molecular relapse was seen before the last follow-up, the median overall follow-up period was 152 (range 131-300) months. In conclusion, recent advances have led to a very good prognosis for children with CP-CML. With TKI treatment, most patients continue their lives without disease progression. Additionally, in selected patients TKI can be discontinued without molecular relapse.
(© 2022. Japanese Society of Hematology.)
Databáze: MEDLINE
Externí odkaz: